Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors)BUNN, Paul A.Seminars in oncology. 2002, Vol 29, Num 3, pp 17-22, issn 0093-7754, SUP9Article

Molecular biology and early diagnosis in lung cancer : Early Invasive Lung Cancer: New Diagnostic Tools and Treatment StrategiesBUNN, Paul A.Lung cancer. 2002, Vol 38, Num 1, pp S5-S8, issn 0169-5002Conference Paper

Recent developments and future directions for research with gemcitabine HCl in the treatment of lung cancer: part 2BUNN, Paul A.Seminars in oncology. 1997, Vol 24, Num 3, issn 0093-7754, 58 p., SUP8Serial Issue

Recent developments and future directions for research with gemcitabine HCl in the treatment of lung cancer: Part 1BUNN, Paul A.Seminars in oncology. 1997, Vol 24, Num 2, issn 0093-7754, 83 p., SUP7Serial Issue

Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why?BUNN, Paul A.Journal of clinical oncology. 2002, Vol 20, Num 18, pp 23s-33s, issn 0732-183X, SUPArticle

Molecular biology and early diagnosis in lung cancer : Early invasive lung cancer: New diagnostic tool and treatment strategiesBUNN, Paul A.Lung cancer. 2002, Vol 38, pp S5-S8, issn 0169-5002, SUP1Conference Paper

Gemcitabine, Pemetrexed, and Targeted Therapies for Solid Tumors: Present and Future PerspectivesBUNN, Paul A.Seminars in oncology. 2002, Vol 29, Num 3, issn 0093-7754, 63 p., SUP9Serial Issue

Targeting epidermal growth factor receptor-tyrosine kinase in the most common solid tumorsBUNN, Paul A.Seminars in oncology. 2003, Vol 30, Num 1, issn 0093-7754, 56 p., SUP1Serial Issue

Future directions in the development of pemetrexedCALVERT, Hilary; BUNN, Paul A.Seminars in oncology. 2002, Vol 29, Num 2, pp 54-61, issn 0093-7754, SUP5Conference Paper

Gemcitabine plus radiotherapy for non-small cell lung cancerGREGOR, A.Seminars in oncology. 1997, Vol 24, Num 3, pp S8-39, issn 0093-7754, -S8-41, SUP8Article

Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scaleCELLA, David.Seminars in oncology. 2003, Vol 30, Num 1, pp 39-48, issn 0093-7754, 10 p., SUP1Article

Pemetrexed, a Novel Multitargeted Antifolate: Current Development and Future DirectionsBUNN, Paul A; CALVERT, Hilary.Seminars in oncology. 2002, Vol 29, Num 2, issn 0093-7754, 62 p., SUP5Conference Proceedings

Present and future treatment of pancreatic cancerHEINEMANN, Volker.Seminars in oncology. 2002, Vol 29, Num 3, pp 23-31, issn 0093-7754, SUP9Article

Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: Preliminary findings in a phase III trial of the Swedish Lung Cancer Study GroupSEDERHOLM, Christer.Seminars in oncology. 2002, Vol 29, Num 3, pp 50-54, issn 0093-7754, SUP9Article

Overview of the randomized phase III trials in non-small cell lung cancer in North AmericaKELLY, K.Seminars in oncology. 1997, Vol 24, Num 3, pp S8-2, issn 0093-7754, -S8-5, SUP8Article

Current perspectives in the treatment of non-small cell lung cancerBUNN, Paul A; KATO, Harubumi.Seminars in oncology. 2001, Vol 28, Num 4, issn 0093-7754, 58 p., SUP14Serial Issue

The present and future of combination chemotherapy in bladder cancerCULINE, Stephane.Seminars in oncology. 2002, Vol 29, Num 3, pp 32-39, issn 0093-7754, SUP9Article

Current status of new agents in the treatment of lung cancerBUNN, Paul A; LE CHEVALIER, Thierry.Seminars in oncology. 1998, Vol 25, Num 4, issn 0093-7754, 93 p., SUP9Serial Issue

Gemcitabine and pemetrexed (Alimta) in thoracic cancers: Present and future perspectives. Introduction and current controversiesLE CHEVALIER, Thierry.Seminars in oncology. 2002, Vol 29, Num 3, pp 43-46, issn 0093-7754, SUP9Article

Expression of target molecules in lung cancer: Challenge for a new treatment paradigmHIRSCH, Fred R; FRANKLIN, Wilbur A; BUNN, Paul A et al.Seminars in oncology. 2002, Vol 29, Num 3, pp 2-8, issn 0093-7754, SUP9Article

Pemetrexed as a single agent in the therapy of advanced lung cancerPOSTMUS, Pieter E; BUNN, Paul A.Seminars in oncology. 2002, Vol 29, Num 2, pp 17-22, issn 0093-7754, SUP5Conference Paper

Phase I studies of ZD1839 in patients with common solid tumorsLORUSSO, Patricia M.Seminars in oncology. 2003, Vol 30, Num 1, pp 21-29, issn 0093-7754, 9 p., SUP1Article

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patientsHERBST, Roy S.Seminars in oncology. 2003, Vol 30, Num 1, pp 30-38, issn 0093-7754, 9 p., SUP1Article

Pemetrexed: Translational research in breast cancerHANAUSKE, Axel R.Seminars in oncology. 2002, Vol 29, Num 3, pp 40-42, issn 0093-7754, SUP9Article

Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975GIACCONE, Giuseppe.Seminars in oncology. 2002, Vol 29, Num 3, pp 47-49, issn 0093-7754, SUP9Article